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Abstract  
 
Carbamazepine (CBZ) causes life-threating T-cell mediated hypersensitivity reactions 
(CBZ-HRs) including serious cutaneous adverse reactions (SCAR) and liver injury 
(CBZ-DILI). In order to evaluate shared or phenotype-specific genetic predisposing 
factors for CBZ-HRs, we performed a meta-analysis of two GWAS studies on  a total 
of 43 well-phenotyped Northern and Southern European CBZ-SCAR cases and 10,701 
population controls and a GWAS on 12 CBZ-DILI cases and 8,438 ethnically-matched 
population controls.  HLA-A*31:01 was identified as the strongest genetic 
predisposing factor for both CBZ-SCAR (OR= 8.0; 95% CI 4.10-15.80; P=1.2x10-9) and 
CBZ-DILI (OR=7.3; 95% CI 2.47-23.67; P=0.0004) in European populations. The 
association with HLA-A*31:01 in SCAR patients was mainly driven by hypersensitivity 
syndrome (OR = 12.9; P=2.1x10-9) rather than by Stevens-Johnson Syndrome/toxic 
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epidermal necolysis (SJS/TEN) cases which showed an association with HLA-B*57:01. 
We also identified a novel risk locus mapping to ALK only for CBZ-SCAR cases which 
needs replication in additional cohorts and functional evaluation.   
 
Introduction  
Carbamazepine (CBZ) is prescribed for epilepsy, trigeminal neuralgia and bipolar 
disorder(1). In 3-10% of patients, CBZ causes a variety of hypersensitivity reactions(2), 
ranging from mild maculopapular exanthemas to hypersensitivity syndrome (known 
as DRESS), acute generalized exanthematous pustulosis (AGEP), Stevens–Johnson 
syndrome (SJS), and toxic epidermal necrolysis (TEN); the latter four phenotypes are 
referred to as serious cutaneous adverse reactions (SCAR). CBZ can also lead to liver 
injury which can occur either as part of DRESS or in isolation (the latter is referred to 
as CBZ-DILI in this paper)(3, 4).  These unpredictable clinical phenotypes are T-cell-
mediated, where CBZ and/or its metabolites bind specific HLA molecules triggering a 
T-cell response(5).  
CBZ-induced SJS/TEN is strongly associated with HLA-B*15:02 in Han Chinese, Thais 
and Malays(6), while HLA-A*24:02 has also recently been identified as a risk factor in 
Han Chinese(7).  HLA-A*31:01 is associated with a variety of CBZ-SCAR phenotypes 
and maculopapular exanthema in Japanese(8), Korean(9) and European-descent 
populations(10).  Several other HLA loci have been suggested as susceptibility loci 
including HLA-A*02:06(8), HLA-B*15:11 (11) and HLA-B*51:01(12-14), but the findings 
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have not always been replicated (15). Currently, we have limited knowledge of 
susceptibility loci for CBZ-DILI.   
The purpose of our study was to perform a meta-analysis between our previously 
published CBZ hypersensitivity cohort (10) and a newly recruited cohort in order to 
increase study power, and futher investigate (i) novel risk loci within and outside the 
HLA region; and (ii) the role of HLA-A*31:01 stratifying by European subpopulations 
and clinical phenotypes including SCAR and DILI.   
 
Results 
Case collection and population structure 
Our meta-analysis included a total of 43 CBZ-SCAR cases and 10,701 population 
controls from two GWAS studies: British GWAS (14 cases and 2,263 controls) and 
broadly-European GWAS (29 SCAR cases and 8,438 controls).  The British GWAS 
included Northern European patients from the UK, which we have reported 
previously (10).  The broadly-European GWAS included a newly recruited set of CBZ-
SCAR cases with diffrent clinical phenotypes (Table 1) and European ancestries 
(Figure S1). The inferred population structure of the combined cohorts is shown in 
Figure 1.  A summary of the clinical characteristics of the SCAR cases is provided in 
Table 1. We analyzed 25 patients with DRESS, 16 patients with Stevens-Johnson 
Syndrome/toxic epidermal necrolysis (SJS/TEN) and 2 cases with acute generalized 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
exanthematous pustulosis (AGEP). The average age of patients at the time of adverse 
reaction was 34 years in both study phases. Nearly two thirds (63%) of cases were 
female.  
Separately, we recruited 12 CBZ-DILI cases of European descent (Figure 1). The type 
of liver injury in these patients was 50% hepatocellular and 50% cholestatic/mixed. 
None of them had cutaneous involvement or eosinophilia. Their clinical 
characteristics are also provided in Table 1. CBZ-DILI cases were compared to the 
8,438 controls from the broadly-European cohort. 
 
Meta-analysis of CBZ-SCAR  
After quality control of the imputed data, we retained 5,271,349 SNPs for association 
analyses. Our meta-analysis identified two loci attaining genome-wide significance (P 
< 5x10-8): 
 The strongest association signal mapped to the MHC (lead SNP rs192543598, 
OR=18.1, 95% CI 8.03-40.90, P=1.7x10-12, Pperm<5x10
-8; Tables 2 and S1 and 
Figures 2 and S2), consistent with our previous result(10).  
 A novel association signal mapping to the ALK gene was observed outside the 
MHC (lead SNP rs187926838, OR=12.1 95% CI [4.94-29.80] P=4.9x10-8, Pperm= 
1x10-7, Table 2 and Figure S3). The intronic lead SNP showed a consistent 
directional effect in both GWASs and was carried by 6% of the cases. The 
imputation for rs187926838 had high accuracy across the imputation batches 
(info score >0.9). The frequency of rs187926838 in our control population was 
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equal to the allele frequency reported in Europeans in gnomad 
(http://gnomad.broadinstitute.org/) and similar across platforms (Table 1 and 
Table S1), confirming the accuracy of the predicted genotypes. rs187926838 
showed a similar frequency in the SANAD cohort (2) which has been exposed 
to a number of antiepileptic drugs including CBZ (AF = 0.005). 
Dissection of the MHC CBZ-SCAR association signal 
The lead SNP representing the MHC CBZ-SCAR association signal, rs192543598, was 
in strong linkage disequilibrium (LD) with HLA-A*31:01 (r2 = 0.75). The HLA class I 
allele also reached genome-wide significance in the meta-analysis (OR=8.0, 95% CI 
[4.10-15.80], P=2.2x10-9, Pperm<5x10
-8, Table 3 and Table S2).  The phase 2 GWAS 
showed a MHC-wide HLA-A*31:01 association, replicating the previously reported 
signal.  
The HLA-A*31:01 association was less significant in the broadly-European cases than 
in the British cases probably because of greater heterogeneity in their geographic 
origin (Figure 1).  A lower allele frequency was observed in the Spanish cases (6%) 
compared to other ethnic groups (15% in Northern European and 13% Italian cases) 
despite an equivalent frequency in the three control groups. However, the effect of 
HLA-A*31:01 was conserved in all European populations (ORItalian=8.7, ORSpanish=3.66, 
ORNorth Europeans=5.51). There were no differences in allele frequencies of the GWAS 
variants in control groups despite the different genotyping arrays used. 
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Reciprocal conditional analyses demonstrated that rs192543598 and HLA-A*31:01 
represent the same underlying association signal (Table S2). After conditioning on 
the lead SNP, rs192543598, we observed some evidence for residual association (at 
locus-wide significance, P<10-5) with CBZ-SCAR, mapping to MUC22 (lead SNP 
rs116071718, OR=4.0, 95% CI [2.25-7.05], P=1.5x10-6, Table S2 and Figure S4.  After 
conditioning on both rs192543598 and rs116071718, the association signal with 
CBZ-SCAR in the MHC was fully accounted for (Figure S4). 
Marginal associations were also identified with HLA-B*51:01 and HLA-C*15:02 (Table 
3).  These HLA alleles along with HLA-A*31:01 constitute an uncommon haplotype 
present in European descent individuals (http://www.allelefrequencies.net). Joint 
carriage of the three alleles had a stronger signal compared to HLA-A*31:01 alone 
(OR=22.1, P=2.4x10-6 vs OR=5.7, P=6.6x10-6, Table S3).   
 
Assessment of polymorphic amino acid residues in HLA molecules 
Predisposition to CBZ-SCAR may be related to the same essential amino acid 
residues in different HLA alleles.  Therefore, we peformed an aggregated 
investigation by analyzing the polymorphic amino-acid residues at these proteins. 
The strongest association was observed for isoleucine73 on the HLA-A locus (OR=5.5, 
95% CI 2.94-10.40, P=1.4x10-7), but could not better explain the CBZ-SCAR 
association than HLA-A*31:01. The AA is shared by the A*33 and A*31 alleles (16). 
Conditional analysis to isoleucine73 or to HLA-A*31:01 revealed that isoleucine80 in 
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the B locus is a new independent factor, and it is shared with HLA-B*57:01 among 
other HLA B alleles(16). After conditioning on both the sites, the residual 
independent association signal was still accounted for by rs116071718 in the MUC22 
gene (Table S4). These AA associations have not previously been found to be 
implicated in genetic predisposition to other ADRs. 
 
GWAS of CBZ-SCAR clinical subtypes 
We stratified the CBZ-SCAR cases by clinical phenotypes (AGEP, DRESS and SJS/TEN, 
see Materials and Methods). The AGEP analysis was not performed since we had only 
two cases, although it is worth noting that one of the two cases was positive for HLA-
A*31:01.  
In the CBZ-DRESS subgroup, HLA-A*31:01 and its proxy SNP, rs192543598, reached 
genome-wide significance (PHLA-A*31:01=2.1x10
-9 and Prs192543598=2.4x10
-13). Consistent 
with the literature (17), HLA-A*31:01 showed a stronger effect with CBZ-DRESS than 
with SJS/TEN (OR=12 vs OR=2.5, respectively, Table 4) with no significant association 
in the latter group.  There was no other phenotype-specific genome-wide significant 
association for both DRESS and SJS-TEN (Figure S5).  
The effect of rs187926838 in the ALK gene was conserved among the CBZ-SCAR 
clinical subtypes (Table S5). We also found that the SJS/TEN phenotype showed a 
MHC-region-wide significant association with HLA-B*57:01 (OR=6.2, 95% CI 2.47-
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15.37, P=9.9x10-5). HLA-B*57:01 was in strong LD (r2=0.8) with the most highly 
associated SNP in the MHC region (rs116347890, OR=11.0, 95%CI 4.62-26.42, 
P=6.6x10-8) but was independent of HLA-A*31:01 (OR=6.4, 95% CI 2.55-16.11, 
P=7.6x10-5, after conditioning on HLA-A*31:01). The polymorphic amino-acid 
position 97 showed an association when valine was present (OR=6.0, 95% CI [2.45-
15.18], P=0.0001). Valine97 is specific for HLA-B*57:01, HLA-B*57:02 and HLA-B*57:03 
and other very rare B57 alleles(16).   
GWAS of CBZ-DILI 
GWAS analysis of 12 European CBZ-DILI cases against 8,438 European controls did 
not identify a genome-wide association because of limited power. However, 33% of 
cases were HLA-A*31:01 carriers (OR=7.3, 95% CI 2.47-23.67, P=0.0004), although the 
OR was less than that seen with DRESS (OR = 12.9). Our prediction of the association 
with HLA-A*31:01 was fully confirmed by HLA sequencing in 11 cases (DNA was no 
longer available in one patient). CBZ-DILI cases did not show an association with 
rs187926838 (in the ALK gene), distinct from that seen with CBZ-SCAR cases (Table 
S5). The most significant amino-acid residues associated with CBZ-DILI were 
isoleucine73 (OR=7.29, 95% CI 2.578-20.6, P=0.0002) and threonine9 (OR=5.5, 95% CI 
2.31-13.14, P=0.0001) at the HLA-A locus. The two residues were in LD (P73I conditional to 
9T = 0.2). Moreover, there was enrichment of HLA-A*31:01 carriers in the 10 CBZ-
SCAR patients with liver involvement compared to the remaining cases (25% vs 12%, 
respectively). 
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Taking all the cases of CBZ-induced hypersensitivity reactions (SCAR and DILI) 
together, the risk of developing either DILI or SCAR when given CBZ was 8-fold 
higher in cases carrying HLA-A*31:01 (OR=8.2, 95% CI 4.56-14.66, P=1.8x10-12, Table 
4).  
 
Discussion 
In the current study, we show that HLA-A*31:01 is the strongest predictor of CBZ-
SCAR in a European-ancestry population, extending our previous study in Northern 
Europeans(10) to include Southern Europeans.  In addition, we also show that (a) 
HLA-A*31:01 seems to predispose to CBZ-induced liver injury; and (b) a variant in the 
ALK gene was associated with an increased risk of CBZ-SCAR, but not CBZ-DILI. 
Our finding of the association between CBZ-SCAR and HLA-A*31:01, initially reported 
in 2011(10), has also been reported by Amstutz et al. in a multiethnic North American 
pediatric cohort(18) and by Genin et al in a European SCAR cohort(17). In our study, 
HLA-A*31:01 was a stronger risk factor for DRESS than SJS/TEN, in line with Genin et 
al(17) (OR=57.6 vs OR=4.4, respectively) and Amstutz et al. (OR=31.5 vs OR=2.8, 
respectively)(18), but not with our original study (OR=12 vs OR=25 respectively)(10) 
where numbers were much smaller.  It is likely that HLA-A*31:01 is the most 
important shared risk factor across CBZ hypersensitivity phenotypes, with the 
strongest predisposition being to DRESS.  Indeed, our meta-analysis shows that HLA-
A*31:01 carriers have eight fold higher risk of developing CBZ-SCAR than non-
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carriers. Interestingly, a recent prospective study in Japan was able to show that pre-
prescription genotyping for HLA-A*31:01 reduces the incidence of CBZ 
hypersensitivity reactions(19). Taken together, the overwhelming evidence of the role 
of HLA-A*31:01 in predisposing to CBZ-SCAR shows that there is a need to 
implement its use in clinical settings, as outlined in the recent CPIC guideline(20). 
Independent of the HLA-A*31:01 association, we identified a residual effect in the 
MHC region mapping to MUC22 gene (lead SNP rs116071718). MUC22 codes for 
panbronchiolitis-related mucin-like protein 1 and has been associated with SJS/TEN 
caused by a variety of drugs including CBZ in European patients(21). Its role in SCAR 
needs further investigation.  We also found that HLA-B*51:01 was the second most 
significant HLA allele. HLA-B*51:01 has already been reported to be marginally 
associated with CBZ-SCAR(12-14) and more recently with SCAR due to other 
drugs(22). HLA-B*51:01 together with HLA-A*31:01 and HLA-C*15:02 constitute a 
haplotype which has a larger OR than each single allele (Table S3).  This is an 
interesting finding which suggests that in vivo, the T cell response to CBZ-derived 
antigens requires cooperativity between different HLA alleles, as we have previously 
demonstrated in an HLA-A*31:01 positive patient(23). 
We also identified an association between CBZ-induced SJS/TEN and HLA-B*57:01.  
This allele is a well-known risk factor for other CD8+ T-cell mediated reactions 
including abacavir hypersensitivity syndrome (24, 25) and flucloxacillin-induced 
DILI(26), and more recently, DILI induced by two other drug combinations, pazopanib 
and a combination of anti-tuberculosis and anti-HIV drugs(27, 28).  Given that the 
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association with CBZ-induced SJS/TEN was not genome-wide significant, it needs 
replication in other cohorts.  Interestingly, our finding of the association of valine97 
with CBZ-SJS/TEN is in line with the association of valine97 with flucloxacillin-DILI (29), 
suggesting that the binding site of HLA-B*57:01 may be promiscuous for a number 
of drugs, which would be in keeping with the increasing number of reports of 
immune-mediated reactions associated with this allele.   
We have for the first time evaluated whether HLA-A*31:01 is a risk factor for DILI.  
Taking all cases of DILI into account, the carriage rate of HLA-A*31:01 was 33% with 
an OR of 7, higher than that found in association of HLA class II alleles with 
lumiracoxib-induced DILI(30). Interestinly, CBZ-SCAR and CBZ-DILI also shared the 
most significant AA, isoleucine73. Isoleucine73 is a cryptic epitope specific for A31 and 
A33 antigens (31). Position 73 is not normally exposed. When the antigen changes its 
conformation and β2m and peptide dissociate from the heavy chain, isoleucine73 is 
externalized with the potential to lead to an autoimmune reaction (32). Interestingly, 
HLA-A*33:01 and HLA-A*33:03 have recently been associated with DILI due to several 
unrelated drugs (33). The association with HLA-A*31:01 however was not genome-
wide significant which may reflect the small numbers studied.  It may also reflect that 
the mechanism of antigen presentation (be it the parent drug or metabolite) differs 
between skin and liver given the major role of the liver in drug metabolism, and its 
ability to form chemically reactive intermediates(34).  Further work in larger numbers 
of patients with CBZ-DILI, together with mechanistic studies, will be needed to 
understand the role of drug/metabolites as antigens in the context of different drug 
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metabolizing and antigen presentation capabilities, and indeed, whether these 
differences are responsible for the remarkable organ-specificity of the reactions, and 
their severity, seen in different patients.    
A tantalizing association that we have identified in our meta-analysis (which did not 
pass genome-wide significance after permutation), which was observed in the SCAR 
but not in the DILI cases, was with uncommon variants in the ALK gene which codes 
for the anaplastic lymphoma kinase gene.  Somatic mutations in the ALK gene have 
been identified in different cancers(35), including lung cancer, which has led to the 
development of ALK-inhibitors for therapy.  The product of the ALK gene, a receptor 
tyrosine kinase belonging to the insulin receptor family, seems to be important for 
the balance between proliferation and apoptosis(36). Furthermore, the associated 
region falls within a keratinocyte-specific predicted insulator (Figure S6). Given that 
ALK is important in cellular proliferation and cell death, and shows ubiquitous tissue 
distribution (http://www.proteinatlas.org/ENSG00000171094-ALK/tissue), it may have 
an important role in T-cell proliferation and keratinocyte death, both important in 
the pathogenesis of SCAR.  
In conclusion, we have provided further data regarding genetic factors predisposing 
to different CBZ adverse reaction phenotypes which are thought to have an immune 
pathogenesis, namely SCAR and DILI.  We have extended our studies to include 
Southern Europeans in addition to our previous study in Northern Europeans(10), 
and included an analysis of CBZ-DILI.  We have also identified novel associations with 
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the ALK and MUC22 genes, which require further validation and experimental 
investigation to determine the mechanisms.  It is possible that there are also other 
genetic factors outside the MHC region, but we may not have had the statistical 
power to detect them in this study. It is therefore important that further work also 
involves a trans-ethnic meta-analysis of the GWAS in diverse populations, which have 
been undertaken to date, to fully assess differences in the genetic architecture of CBZ 
adverse reactions between ancestries and more precisely localize the underlying 
causal alleles.  
 
Methods 
Study design overview 
Our study combines results from two GWAS conducted in subjects with ancestry 
from Northern Europe, Italy and Spain. All participants provided written informed 
consent and each study was approved by the appropriate national or institutional 
ethical review boards. Since the reactions has a very low prevalence, we used general 
population samples as study controls. 
 
British CBZ-SCAR GWAS 
The study included 14 cases of CBZ-hypersensitivity of Northern European descent of 
out the 21 recruited at the University of Liverpool as described by McCormack et 
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al(10). A total of 2,263 population controls of Northern European descent from the 
Wellcome Trust Case Control Consortium (WTCCC) were utilized. The other Liverpool 
samples (n=7) originally described were excluded either because of population 
stratification issues or because 2 patients had DILI rather than skin invovlement (and 
so have been included in the liver analysis). 
 
Broadly-European CBZ-SCAR GWAS 
The study included a total of CBZ-SCAR 29 samples obtained from two available 
sources: 3 cases were from the PGX40001 study(37) and 26 were newly recruited 
between 2009 and 2013 as part of ITCH. The ITCH study was run under the auspices 
of the International Serious Adverse Event Consortium, involving 12 recruitment 
centers in Europe, Australia and South America. Clinical inclusion criteria for all ITCH 
related SCAR cases were as described by our previous phenotype standardization 
protocol for drug-induced skin injury(38). All patient phenotypes were independently 
adjudicated by NS and PF.  Further clinical details are provided in Table 1. 
For this group, a total of 8,438 population controls of European descent were 
selected from the WTCCC (not overlapping with samples from the British cohort), the 
population reference sample (POPRES)(39), the PGX40001 study(37), the Spanish 
Bladder Cohort (dbGaP phs000346.v1)(40), the Hypergenes cohort 
(http://www.hypergenes.eu), the National Spanish DNA Bank cohort 
(http://www.bancoadn.org/), the Swedish Twin Registry cohort 
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(http://ki.se/en/research/the-swedish-twin-registry), LAM30004 study(37), TSI 
(Hapmap data) and the iSAEC Italian Penicillin Tolerant Cohort (IPTC).  
 
Broadly-European CBZ-DILI GWAS 
As part of the phase 2 study, we also collected 12 European descent CBZ-DILI cases, 
where the liver was involved by itself. The cases were recruited from two large 
international DILI consortia: iDILIC and DILIN(33), while two other cases were as 
described previously(10).  The iDILIC cases were evaluated by application of the 
Council for International Organizations of Medical Science (CIOMS) scale, also called 
the Roussel Uclaf Causality Assessment Method (RUCAM) and by expert review by a 
panel of three hepatologists. Only cases having at least possible causality (score ≥3) 
were included in the study(33).  DILIN causality assessment is determined by a panel 
of three hepatologists who independently assign a causality score ranging from 1 
(definite) to 5 (unlikely) as well as a severity score ranging from 1 (mild) to 5 (fatal) as 
previously described(33). Beside the  DILI phenotype, DILIN and iDILIC also collected 
additional clinical information including the occurrence of eosinophilia and 
cutaneous involvement. The cases were compared with the 8,438 phase 2 population 
controls of European descent. 
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Genotyping of cases and controls 
Out of the cumulative 43 CBZ-SCAR cases, 3 PGX40001 cases were previously 
genotyped with Illumina 1M Duo chip(41). DNA from the rest of British and broadly-
European cases was extracted from whole blood and stored in the Wolfson Centre 
for Personalized Medicine in Liverpool. Genome-wide genotyping was profiled by the 
Illumina Infinium HumanCoreExome Bead Chip for 16 cases and by Illumina 
HumanOmniExpress Bead Chip for 24 cases at the Broad Institute, Boston. Among 
the CBZ-DILI cases, 3 cases were previously genotyped with Illumina 1M Duo chip 
while 2 cases were newly profiled by HumanCoreExome Bead Chip and 7 cases by 
HumanOmniExpress Bead Chip at the Broad Institute, Boston(33). A total of 10,701 
previously genotyped population controls were cumulatively used in British and 
broadly-European cohorts. Information about the genotyping platform used by each 
of the control cohorts is reported in Table S6. For each of the sample batches 
(defined as a set of subjects - either cases or controls -  genotyped together by the 
same array), quality control was conducted at both SNP and subject levels before 
performing the imputation as previusly described(41).  Analysis of population 
structure was performed by the EIGENSTRAT package (version 3.0)(42). Pre-phasing 
and imputation were performed in batches by dividing the cases and controls 
according to genotyping platform, using SHAPEIT (version v2.r727)(43) and IMPUTE2 
(version 3)(44) with 1000 Genomes Project (release v3) as reference(43). For 
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downsteam analysis, we used best-guess genotypes retaining imputed genotypes with 
posterior probability > 0.9. Detailed methods are outlined in the Supplemetary 
Materials. 
 
Association analysis and meta-analysis 
We tested for association of each SNP with CBZ-SCAR, separately in British and 
broadly-European GWAS, in a logistic regression framework, under an additive 
genetic model, with adjustment for the principal components from smartPCA to 
account for population structure using using PLINK v 1.07(45). No other additional 
covariates were included in the model since we did not have clinical information for 
controls. Association summary statistics from the two phases were combined using 
effective sample size weighted Z-score fixed-effects meta-analysis, implemented in 
METAL(46).  Allelic ORs across the two phases were obtained through inverse-
variance weighting of effect sizes, with heterogeneity assessed with Cochran’s Q 
statistic(47), implemented in METAL. We reported only those SNPs that attained, in 
addition to genome-wide significance, nominal evidence of association (P<0.05) with 
the same direction of effect on CBZ-SCAR in both GWAS phases (internal validation).  
Further, we tested for association of each SNP with CBZ-SCAR clinical subtypes: 
SJS/TEN in phase 2 GWAS and DRESS across both phases in the same meta-analysis 
framework. We also tested for association of each SNP with CBZ-DILI in phase 2 
GWAS, in a logistic regression framework, under an additive genetic model, with 
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adjustment for the principal components to account for population structure. 
Genome-wide significance was defined using a common threshold of P<5x10-8. To 
account for the small samples size and the disproportionate case/control ratio, we 
applied a permuation approach for genome-wide significant signals. In particular, we 
randomly permuted genotypes amongst individuals within the same phase of the 
design, tested for association and then meta-analysed . We applied 5x108 
permutations to demonstrate genome-wide significance.  All detailed analyses and 
Manhattan plots were performed with R (Version 3.0.2)(14).  
 
HLA imputation, genotyping and analysis 
For each batch, HLA alleles were inferred using HIBAG(48) using the reference 
predictor panels specific for the genotyping chip. Amino acid (AA) changes were 
inferred by SNP2HLA using reference data collected by the Type 1 Diabetes Genetics 
Consortium (T1DGC)(49). We tested for association of carriage of each 
allele/AA/specific HLA haplotypes with CBZ-SCAR, CBZ-SCAR subtypes and CBZ-DILI 
using the same methods described above. MHC significance was defined using the 
Bonferroni correction threshold of P<0.00025 accounting for 200 observed HLA 
alleles across loci (0.05/200). Conditional analyses in the MHC region were 
undertaken and the genotypes at the conditioning SNP(s) were included as 
covariates under an additive model.  Fixed-effects meta-analyses across the two 
phases of GWAS were performed using the methods described above for 
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unconditional analyses. High resolution genotyping of HLA loci was performed on all 
DILI cases by Histogenetics (Ossining, New York) as previusly described (33). 
 
 
Study Highlights  
What is the current knowledge on the topic? 
Carbamazepine (CBZ) is associated with serious, and sometimes fatal, cutaneous and 
liver adverse reactions.  Genome wide profiling has shown that these predisposing 
factors largely reside in the HLA region (HLA-B*15:02 and HLA-A*31:01) consistent 
with the immune pathogenesis. 
 
What question did this study address? 
What are the genetic predisposing factors in Northern and Southern European 
populations for carbamazepine-induced hypersensitivity reactions affecting both the 
skin and liver?  
 
What does this study add to our knowledge? 
Genetic profiling confirmed that HLA-A*31:01 predisposes to serious cutaneous 
adverse reactions (SCAR) in both Northern and Southern European populations.  
HLA-A*31:01 also seems to be predispose to carbamazepine-induced liver injury.  In 
addition, an uncommon variant in the ALK gene was associated with an increased 
risk of CBZ-SCAR. 
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How might this change clinical pharmacology or translational science? 
Our study adds to the overwhelming evidence of the role of HLA-A*31:01 in 
predisposing to a variety of CBZ hypersensitivity phenotypes, and highlights the 
need to implement its pre-prescription and pre-emptive use in clinical settings. 
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Figures 
 
Figure 1 Scatterplot representing the first two principal components of the 
current study cohort.  
Colored dots are the cases divided by clinical phenotypes and the grey dots are the 
controls. The controls cluster in four groups representing the Italian, Spanish, UK and 
Swedish major control populations. 
 
Figure 2 Manhattan plot displaying the results of the meta-analysis of British 
and broadly-European CBZ-SCAR GWAS analysis. SNPs in red have a significance 
level less than 5x10-8. 
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